Equities

MannKind Corp

MannKind Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.53
  • Today's Change-0.10 / -2.16%
  • Shares traded2.58m
  • 1 Year change+12.97%
  • Beta1.2769
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

  • Revenue in USD (TTM)198.96m
  • Net income in USD-11.94m
  • Incorporated1991
  • Employees414.00
  • Location
    MannKind Corp1 Casper StreetDANBURY 06810United StatesUSA
  • Phone+1 (818) 661-5000
  • Fax+1 (302) 636-5454
  • Websitehttps://mannkindcorp.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mirum Pharmaceuticals Inc186.37m-163.42m1.18bn264.00--4.72--6.34-4.08-4.084.565.320.37293.374.05705,962.10-32.70-38.93-38.55-44.8874.76---87.68-190.714.19-79.670.552--141.85---20.45--21.81--
Belite Bio Inc (ADR)0.00-31.63m1.19bn20.00--12.87-----1.24-1.240.003.100.00----0.00-45.54---47.50--------------0.00-------150.09------
Scholar Rock Holding Corp0.00-165.79m1.20bn150.00--5.21-----1.99-1.990.002.960.00----0.00-49.55-38.14-55.26-44.31-------647.95----0.1817---100.00---23.26---45.61--
Pharvaris NV0.00-116.19m1.22bn65.00--5.81-----3.18-3.180.004.040.00----0.00-57.65---63.41-------------6.960.0019-------78.64------
Deciphera Pharmaceuticals Inc163.36m-194.94m1.23bn355.00--3.48--7.51-2.29-2.291.924.360.35220.17876.01460,157.80-42.03-44.54-52.63-52.2497.72---119.34-245.883.59--0.00--21.87---8.95---7.11--
MannKind Corp198.96m-11.94m1.25bn414.00------6.29-0.0464-0.04640.7087-0.91160.51652.5012.55480,584.50-3.10-26.07-3.99-37.8068.4559.68-6.00-57.613.310.50231.90--99.4248.1786.34--160.47--
Ligand Pharmaceuticals Inc131.31m53.82m1.26bn58.0024.521.7913.979.612.912.817.2639.920.16950.56424.152,264,035.006.9412.327.5012.9991.9981.6540.9880.3212.72--0.00001---33.09-12.181,131.21-17.8642.63--
Tarsus Pharmaceuticals Inc17.45m-135.89m1.30bn244.00--6.00--74.29-4.58-4.580.59395.760.0707--1.6471,504.10-55.09-31.56-61.63-33.8290.87---778.89-242.596.85--0.1315---32.42---118.86--279.39--
Collegium Pharmaceutical Inc566.77m48.16m1.31bn197.0046.376.676.622.310.88230.882312.536.130.48916.103.132,876,990.004.162.796.754.8057.5550.888.505.161.102.590.77340.0022.1715.11292.60---54.77--
AbCellera Biologics Inc38.03m-146.40m1.31bn586.00--1.13--34.57-0.5062-0.50620.13153.960.0251--1.1064,890.79-9.676.08-10.496.67-----384.9924.697.32--0.000.00-92.1733.91-192.35--70.96--
Gyre Therapeutics Inc0.00-44.24m1.34bn7.00---------20.60-20.600.001.390.00----0.00-215.90-58.25-235.61-72.12-------817.06----0.00---89.18-4.8590.63------
Ironwood Pharmaceuticals, Inc.442.74m-1.00bn1.35bn267.00------3.05-6.51-6.512.59-2.210.5634--3.621,658,184.00-131.28-4.54-162.45-5.20-----233.00-7.81--63.791.98--7.835.02-672.50--160.10--
Pacira Biosciences Inc674.98m41.96m1.35bn711.0042.781.5511.482.000.67890.678912.3318.720.41471.846.62949,336.102.583.352.793.9872.6472.636.228.574.179.850.37520.001.2214.88163.72--0.8761--
Prothena Corporation PLC91.37m-147.03m1.35bn173.00--2.41--14.79-2.80-2.801.6810.460.1256----528,150.30-20.22-14.20-21.82-15.11-----160.92-111.02----0.00--69.50148.98-25.72--9.71--
Spyre Therapeutics Inc886.00k-338.79m1.35bn30.00------1,528.43-75.04-75.040.12857.450.0043--4.7329,533.33-164.06-101.87-184.94-118.83-----38,238.15-2,949.59----0.00---61.96-25.61-304.21------
Data as of Mar 28 2024. Currency figures normalised to MannKind Corp's reporting currency: US Dollar USD

Institutional shareholders

32.31%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 202320.19m7.47%
The Vanguard Group, Inc.as of 31 Dec 202314.58m5.39%
SSgA Funds Management, Inc.as of 31 Dec 202312.94m4.79%
Nitorum Capital LPas of 31 Dec 202310.83m4.01%
Avoro Capital Advisor LLCas of 31 Dec 20239.00m3.33%
Fidelity Management & Research Co. LLCas of 31 Dec 20235.94m2.20%
Geode Capital Management LLCas of 31 Dec 20235.84m2.16%
D. E. Shaw & Co. LPas of 31 Dec 20232.99m1.11%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 20232.55m0.94%
Parkman Healthcare Partners LLCas of 31 Dec 20232.50m0.92%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.